Last reviewed · How we verify
NCT06198998
CorVad Percutaneous Ventricular Assist System Study
NA trial testing CorVad Percutaneous Ventricular Assist System in Coronary Artery Disease in 120 participants. Status unknown.
18 October 2024
Quick facts
| Lead sponsor | Shenzhen Core Medical Technology CO.,LTD. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 19 October 2023 |
| Primary completion | 18 October 2024 |
| Estimated completion | 18 October 2024 |
| Sites | 12 locations across China |
Drugs / interventions tested
- CorVad Percutaneous Ventricular Assist System
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
Sponsor
Shenzhen Core Medical Technology CO.,LTD.
Who can join
Adults 18 to 90, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the safety and effectiveness of the CorVad Percutaneous Ventricular Assist System for short-term ventricular support during high-risk percutaneous coronary intervention (HRPCI) in non-emergent, hemodynamically stable coronary artery disease patients via a prospective, multicenter, single-arm clinical trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06198998
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CorVad Percutaneous Ventricular Assist System
Trials testing the same drug.
- NCT06646224 — Efficacy and Safety of the CorVad Percutaneous Ventricular Assist System in Cardiogenic Shock · NA · recruiting
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Shenzhen Core Medical Technology CO.,LTD. trials
Trials by the same sponsor.
- NCT07233876 — DuoCor 2 DOMINATE Study · NA · not yet recruiting
- NCT06886113 — CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial · NA · not yet recruiting
- NCT06646224 — Efficacy and Safety of the CorVad Percutaneous Ventricular Assist System in Cardiogenic Shock · NA · recruiting
- NCT06878508 — DuoCor Ventricular Assist System Early Feasibility Study · NA · recruiting
- NCT05876000 — Corheart 6 LVAS Study · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06198998 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen Core Medical Technology CO.,LTD.
- Last refreshed: 10 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06198998.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing